Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Acrc Trials

Neither a doctor nor a teaching hospital

Research payments

$4,535,436

361 payments

Through program year 2025, Acrc Trials is reported as receiving $4,535,436 in research payments, across 361 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,628,432 155
2024 Research $1,375,531 34
2023 Research $87,851 42
2022 Research $34,073 10
2021 Research $92,138 15
2020 Research $78,918 39
2019 Research $1,238,493 66

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $2,854,453 157 payments
  2. Romark Laboratories, LC $916,485 7 payments
  3. Sanofi US Services Inc. $348,042 75 payments
  4. GlaxoSmithKline, LLC. $235,053 84 payments
  5. AstraZeneca Pharmaceuticals LP $59,307 4 payments
  6. Incyte Corporation $42,460 10 payments
  7. Novartis Pharmaceuticals Corporation $30,135 4 payments
  8. Pfizer Inc. $23,213 5 payments
  9. Seqirus USA Inc $18,089 6 payments
  10. Merck Sharp & Dohme Corporation $8,035 8 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $1,446,906 109 payments
  2. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $1,261,501 13 payments
  3. Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection $650,314 3 payments
  4. A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza $266,171 4 payments
  5. A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr $221,608 21 payments
  6. A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, DO $76,590 38 payments
  7. A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr $72,269 32 payments
  8. A Phase III, Randomized, Controlled, Observer-Blind Study to Evaluate $65,464 7 payments
  9. A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease $65,420 5 payments
  10. Phase 3B, Randomized, Observer-Blind. Multicenter Study to Assess the $63,153 22 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record